Covaxin depicts 81 percent efficacy for the phase 3 clinical trials: Bharat Biotech

Photo Credits: AP

Hyderabad-based Bharat Biotech, developed the first ‘Made in India vaccine’ called Covaxin, which has been discovered to have an efficacy of 81 per cent for the phase three clinical trials with the preliminary results as announced on Wednesday.

The clinical trials involved 25,800 subjects in collaboration with the Indian Council of Medical Research (ICMR).

Krishna Ella, chairman and managing director of Bharat Biotech said, “Today is an important milestone in vaccine discovery, for science and our fight against coronavirus disease. With today’s results from our phase 3 clinical trials, we have now reported data on our Covid-19 vaccine from phase 1, 2, and 3 trials involving around 27,000 participants. Covaxin demonstrates a high clinical efficacy trend against Covid-19 but also significant immunogenicity against the rapidly emerging variants.”

The vaccine can be subjected to storage in the range of 2 to 7 degree Celsius and is supplied in a ready-to-use liquid formulation which allows distribution through existing vaccine supply chain channels.

Bharat Biotech, in a statement said, “BBV152 is based on an established manufacturing platform with a better safety profile when compared to other vaccine platforms. The inclusion of the Algel-IMDG adjuvant enhances T-cell immune responses to Covid-19, leading to long-term protection.”

• Ravichandran Ashwin Announces Sudden Retirement from International Cricket
• Free Cancer Vaccine Distribution in Russia from 2025: A Remarkable Medical Breakthrough
• Train Services Delayed Between Bengaluru-Mysuru: Introduction of New Train Numbers
• One Nation, One Election Bill Presented in Lok Sabha: Strong Opposition from Parties
• Tragic Accident in Raichur: Overturned Lorry Kills Three PWD Officials